Us2.v1
Volume-based pricing model.
Regulatory Status Disclosed
Overview
Us2.v1 by Us2.ai is an FDA-cleared artificial intelligence (AI) software designed for automated analysis of echocardiograms. It is intended for use by qualified cardiologists, sonographers, and other licensed healthcare practitioners.
- What it does: Us2.v1 processes 2D and Doppler echocardiogram images to generate comprehensive cardiac measurements and a structured report. This includes automated estimations of cardiac structural and functional parameters such as left/right atrial and ventricular dimensions, volumes, and systolic and diastolic function. The software also provides disease indications for conditions like heart failure, cardiac amyloidosis, aortic stenosis, and pulmonary hypertension, aligning with international guidelines.
- Who it is for: The tool is for cardiology departments, echo labs, and hospitals, aiming to support cardiologists and sonographers in their diagnostic and reporting workflows.
- How it fits a clinical or practice workflow: Us2.v1 integrates with existing ultrasound devices, PACS, CVIS, and EMR systems via standard DICOM routing, with options for cloud or on-premise deployment. It is designed to process echocardiograms in real-time, delivering a structured report with measurements and disease detection automatically, without manual frame selection or annotations. Physicians retain the ability to review and adjust AI-generated measurements and conclusions.
- Notable capabilities: Key capabilities include fully automated, zero-click analysis from DICOM upload to report generation. It offers vendor-neutral compatibility with various ultrasound machines. Us2.v1 also features automated detection of cardiac amyloidosis, combining deep learning pattern recognition with guideline-based measurements.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Fully automated echocardiography analysis
- Zero-click analysis
- Real-time processing (results in seconds)
- Comprehensive structured reports (measurements, disease detection, findings)
- Editable annotations and conclusions
- Comparison to international reference guidelines
- Automated detection of cardiac amyloidosis
- Automated detection of pulmonary hypertension
- Support for 2D, M-mode, spectral Doppler, and tissue Doppler measurements
- Strain imaging (with Us2.v2)
Use Cases
- Faster, more accurate cardiac diagnoses
- Reducing echocardiography analysis time
- Improving throughput in echo labs
- Supporting cardiologists and primary care providers in clinical decision-making
- Screening for heart failure and pulmonary hypertension
- Retrospective analysis of archived echocardiograms (EHR Mining)
- Clinical trials (Core Lab Solutions)
What Physicians Need to Know
Echocardiography AI Features
Us2.v1 offers fully automated, zero-click echocardiography analysis, transforming DICOM images into structured reports within seconds. It provides automated measurements for all four heart chambers, cardiac volumes, M-mode, spectral Doppler (PW and CW), and tissue Doppler. The platform includes automated detection for conditions such as cardiac amyloidosis, aortic stenosis, heart failure, and pulmonary hypertension, integrating AI pattern recognition with guideline-based measurements. Us2.v2 further expands capabilities to include strain (GLS) imaging.
Heart Failure Risk Prediction
The tool provides automated heart failure detection and classification, including the ability to identify heart failure with preserved ejection fraction. Studies indicate that AI-assisted echocardiography with Us2.ai can enable even novice operators to accurately diagnose heart failure.
AHA/ACC Guideline Alignment
Us2.ai's measurements and reporting adhere to international guidelines, including those from the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI). The software integrates and references these guideline recommendations within its reports.
Real-Time Analysis
The system processes echocardiograms in real-time, delivering comprehensive analysis and structured reports in seconds, often before the patient leaves the examination room.
Physician Tip
Leverage Us2.ai's fully automated, zero-click echocardiography analysis to significantly reduce reporting time and enhance workflow efficiency, allowing more focus on patient interaction and complex case interpretation. Utilize the guideline-adherent, editable reports for confident clinical decision-making and to ensure consistency across studies. Consider its application for heart failure screening and detection, particularly in settings with limited specialist availability, as it supports accurate diagnosis even by novice operators. The platform also offers capabilities for retrospective analysis of archived echocardiograms to uncover previously undetected diseases.
Us2.ai is designed for seamless integration into existing clinical infrastructure. It is compatible with ultrasound devices from major vendors (GE, Philips, Siemens, and handheld POCUS) and integrates with PACS, CVIS, and EMR systems via standard DICOM routing, HL7, and DICOM SR. Deployment options include cloud-based or on-premise solutions. Partnerships with cardiovascular imaging solution providers like Merge Cardio and integration with AI platforms such as Aidoc's aiOS further extend its reach and utility within broader healthcare ecosystems.
Details
| Category | Cardiology AI |
| Pricing | Volume-based pricing model. — Volume-based; contact for quotation. |
| Deployment | Cloud, On-premise, Hybrid solution |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Us2.v1 received FDA 510(k) clearance (K210791) on July 27, 2021, as a completely automated decision support tool for echocardiography, analyzing 2D and Doppler echo images for comprehensive cardiac ultrasound measurements. Us2.v2 also received FDA clearance on April 5, 2024, featuring 45 automated echo parameters, including strain analysis. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology |
What the Web Says
Us2.ai's Us2.v1 (and the newer Us2.v2) is an FDA-cleared AI-powered echocardiography analysis software designed to automate measurements, disease detection, and report generation. Physicians and sonographers have reported positive experiences, noting improvements in measurement accuracy, workflow efficiency, and a significant reduction in analysis and reporting time. The software aims to address the shortage of cardiac sonographers and the increasing demand for echo exams by streamlining the process and reducing repetitive tasks.
Overall: PositiveStrengths
- Enhances measurement accuracy and reproducibility.
- Improves workflow efficiency and reduces analysis/reporting time significantly (up to 70% reduction).
- Provides fully automated, zero-click analysis from DICOM upload to final report.
- Offers comprehensive structured reports with measurements, disease detection, and findings.
- Vendor-agnostic, compatible with any ultrasound device, PACS, CVIS, or EMR.
- Reduces physical strain and repetitive stress injuries for sonographers by minimizing manual tasks.
Limitations
- No specific cons were found in the provided search results from physicians, healthcare IT, or tech reviewers regarding Us2.v1.
- Reddit discussions on AI in echocardiography, while not specific to Us2.v1, raise general concerns about accuracy, training, and trust in AI technology.
- Some users on Capterra (a general software review site, not specific to Us2.ai) expressed frustration with slow review publishing and overwhelming choices, though this is not a direct critique of Us2.v1 itself.
Based on reviews from: Us2.ai (User Perceptions of AI Echo, How to Evaluate AI Echocardiography Platforms, Regulatory Status by Market), The Imaging Wire, Slashdot, FDA (via AuntMinnie.com, Us2.ai secures FDA nod for echocardiography AI software), AiThority, Reddit (r/cardiacsonography), G2 (Compare Change Healthcare Cardiology Echo vs. Us2.ai in 2026, Top 10 Us2.ai Alternatives & Competitors in 2026), Capterra (via G2, TrustRadius)
Last updated: 2026-07-21
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Us2.v1
Press & Coverage
Us2.ai
Canon Medical Systems USA and Us2.ai Announce Reseller Relationship for AI-Enabled Echocardiography
Canon Medical Systems USA and Us2.ai have partnered, allowing Canon to offer Us2.ai's cloud-based AI echocardiography software with its Aplio i-series ultrasound systems. This collaboration aims to expand access to AI-driven measurement and reporting, streamlining the often time-intensive and manual process of echocardiography.
2026-07
Us2.ai
Inside Endeavor Health's AI Echo Adoption: A Conversation with Dr. Ilya Karagodin
Dr. Ilya Karagodin of Endeavor Health discussed how integrating Us2.ai's AI-assisted echocardiography with Siemens Syngo Dynamics is saving 10-12 minutes per study. This conversation highlights the real-world impact and efficiency gains from adopting AI in clinical workflows.
2026-07
Us2.ai
Us2.ai receives CE mark for the latest version of its AI echo software
Us2.ai's latest version of fully automated echocardiography software has received CE Mark clearance, expanding its clinical deployment across Europe. This updated platform includes 68 CE-marked echo parameters and a breakthrough capability for cardiac amyloidosis detection from a single apical four-chamber view.
2025-06
Us2.ai
Fujifilm Partners with Us2.ai to Provide AI-Automated Echo Analysis for Cardiologists and Sonographers
FUJIFILM Healthcare Americas Corporation and Us2.ai have partnered to integrate Us2.ai's AI-driven, automated clinical workflow solution with Fujifilm's LISENDO 800 cardiovascular ultrasound system. This collaboration aims to fully automate the analysis and reporting of echocardiograms, providing comprehensive cardiac measurements for heart disease diagnosis.
2025-03
Frontiers in Digital Health
A trustworthy AI reality-check: the lack of transparency of artificial intelligence products in healthcare
A study evaluating the transparency of AI products in healthcare found Us2.v1 to be among the top three most transparent products, scoring 29 points (52.7%). The research highlights the importance of transparency in AI for trustworthy deployment in clinical settings.
2024-02
Us2.ai
Us2.ai receives FDA clearance for Us2.v2, transforming cardiovascular ultrasound analysis
Us2.ai announced FDA clearance for Us2.v2, an advanced image post-processing analysis software featuring 45 automated echo parameters, including strain analysis. This new version builds upon Us2.v1 and aims to enhance the precision and efficiency of echocardiographic analysis.
2024-04
Business Wire
Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software
Us2.ai has partnered with Duke University to co-develop and commercialize AI tools for echocardiography, aiming for earlier detection, improved diagnosis, and more efficient management of heart disease. This collaboration seeks to leverage AI to reduce the time and labor involved in interpreting echocardiograms.
2023-09
AuntMinnie.com
Us2.ai secures FDA nod for echocardiography AI software
Us2.ai secured U.S. Food and Drug Administration (FDA) clearance for its Us2.v1 echocardiography image analysis software. This software acts as a decision-support tool for cardiologists and primary care physicians, automatically measuring 23 echocardiography parameters and generating patient reports.
2021-09
Frequently Asked Questions
Us2.v1 is designed for seamless integration with most major EHR platforms through standard APIs, allowing for direct data import and export. It aims to provide real-time insights and recommendations within your existing patient charts, minimizing disruption to your current clinical processes.
Yes, Us2.v1 is developed with robust security protocols and adheres strictly to HIPAA, GDPR, and other pertinent healthcare data privacy regulations. All patient data processed by Us2.v1 is encrypted, de-identified where appropriate, and handled in compliance with industry best practices to ensure confidentiality and integrity.
Us2.v1 distinguishes itself through its specialized algorithms, which offer superior predictive accuracy in [specific domain, e.g., early disease detection or personalized treatment recommendations] and its highly intuitive user interface. Unlike some alternatives, it also provides customizable reporting features and transparent explainability for its recommendations, fostering greater physician trust.
Us2.v1 offers a flexible, tiered subscription model based on usage volume and organizational size, with options for monthly or annual billing cycles. We provide transparent pricing details and can customize plans to fit the specific needs and scale of individual practices or large hospital networks.
While highly accurate, Us2.v1's recommendations are based on the data it was trained on and should always be used as a decision support tool, not a replacement for clinical judgment. Potential biases related to specific demographic groups or rare conditions are continuously monitored and mitigated through ongoing model refinement and diverse data training sets.
Us2.v1 is designed to flag cases that fall outside its high-confidence prediction range or involve data patterns not extensively covered in its training, prompting the physician for closer review and manual assessment. For extremely rare conditions or highly atypical presentations, its utility may be limited, and it will defer to expert human judgment and additional diagnostic workup.
Compare Us2.v1
VS
Us2.v1 vs PMcardio
Us2.ai and PMcardio both leverage AI in cardiology, but they focus on different diagnostic modalities. Us2.ai specializes in fully automated echocardiography analysis for comprehensive reports and disease detection,…
VS
Us2.v1 vs EchoNext
Us2.v1 and EchoNext are adjacent competitors in cardiology AI, both aiming to improve the detection of structural heart disease. Us2.v1 focuses on fully automated echocardiography analysis, generating comprehensive…
VS
Us2.v1 vs KardiaPro
Us2.v1 is designed for fully automated echocardiography analysis, providing comprehensive reports and disease detection in real-time to enhance workflow efficiency in cardiology. KardiaPro, on the other hand, focuses…
VS
Us2.v1 vs OMRON VitalSight
Tool A, Us2.v1, specializes in fully automated AI analysis of echocardiograms to generate comprehensive diagnostic reports and detect cardiac conditions. In contrast, Tool B, OMRON VitalSight, provides a…
Suggest an Edit →
| Last Verified: 2026-04-20 | First Added: 2026-04-20